Deal overview
| Target | DAIICHI SANKYO (DS-1062 RIGHTS) |
|---|---|
| Bidder | ASTRAZENECA PLC |
| Price | £60.00 Full version or £25.00 Light version |
| Publication Date | Jul 27, 2020 |
| Abstract | On 27 July 2020, it was announced that the UK quoted pharmaceuticals group AstraZeneca Plc ("AstraZeneca"), had entered into a global development and commercialisation collaboration agreement with the Japanese quoted pharmaceuticals group Daiichi Sankyo Company, Limited ("Daiichi Sankyo") for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 ... |
| Number of pages (Full version) | 6 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
